Filter By:

Binimetinib

09/27/2015

European Cancer Congress

LOGIC2: Phase 2, Multi-center, Open-label Study of Sequential Encorafenib/Binimetinib Combination Followed by a Rational Combination with Targeted Agents After Progression, to Overcome Resistance in Adult Patients with Locally Advanced or Metastatic BRAF V600 Melanoma

R. Dummer, et al.

Encorafenib

07/04/2015

ESMO World Congress of Gastrointestinal Cancer

Phase 1b/2 Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab With or Without the α‐Specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF‐Mutant Colorectal Cancer

E. Elez, et al.

ARRY-380

06/01/2015

American Society of Clinical Oncology Meeting

ONT-380 in the Treatment of HER2+ Breast Cancer Central Nervous System (CNS) Metastases (Mets)

C. Ferrario, et al.

Binimetinib

05/31/2015

American Society of Clinical Oncology Meeting

SUCCESSFUL IMPLEMENTATION OF A NOVEL TRIAL MODEL – THE SIGNATURE PROGRAM

J. Peguero, et al.

Filanesib

05/31/2015

American Society of Clinical Oncology Meeting

The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma

S. Lonial, MD, et al.

Filanesib

05/31/2015

American Society of Clinical Oncology Meeting

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma

J. A. Zonder, MD, et al.

Encorafenib

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1/b2 Study of BRAF Inhibitor (BRAFi) Encorafenib (ENCO) Plus MEK Inhibitor (MEKi) Binimetinib (BINI) in Cutaneous Melanoma Patients Naive to BRAFI Treatment

R. Sullivan, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A phase Ib/II study of MEK162 (binimetinib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)

P.Chi, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

B. J. Monk, MD, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1b dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

R. N. Grisham, MD, et al.